RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
DOD Biotech PCL Stock

DOD Biotech PCL Net Income 2024

DOD Biotech PCL Net Income

7.19 M THB

Ticker

DOD.BK

ISIN

TH8569010003

In 2024, DOD Biotech PCL's profit amounted to 7.19 M THB, a -101.8% increase from the -398.33 M THB profit recorded in the previous year.

The DOD Biotech PCL Net Income history

YEARNET INCOME (undefined THB)
20237.19
2022-398.33
202149.79
2020141.25
201986.71
2018305.26
2017142.19
2016138.78
2015128.89
201447.27

DOD Biotech PCL Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into DOD Biotech PCL, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by DOD Biotech PCL from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects DOD Biotech PCL’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of DOD Biotech PCL. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into DOD Biotech PCL’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing DOD Biotech PCL’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on DOD Biotech PCL’s growth potential.

DOD Biotech PCL Revenue, EBIT and net profit per share

DateDOD Biotech PCL RevenueDOD Biotech PCL EBITDOD Biotech PCL Net Income
2023678.15 M undefined56.89 M undefined7.19 M undefined
2022537.16 M undefined-11.38 M undefined-398.33 M undefined
20211.02 B undefined310.81 M undefined49.79 M undefined
20201.08 B undefined356.82 M undefined141.25 M undefined
2019789.92 M undefined86.22 M undefined86.71 M undefined
2018666.36 M undefined304.6 M undefined305.26 M undefined
2017387.35 M undefined149.31 M undefined142.19 M undefined
2016367.58 M undefined138.09 M undefined138.78 M undefined
2015384.87 M undefined131.77 M undefined128.89 M undefined
2014169.72 M undefined47.27 M undefined47.27 M undefined

DOD Biotech PCL stock margins

The DOD Biotech PCL margin analysis displays the gross margin, EBIT margin, as well as the profit margin of DOD Biotech PCL. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for DOD Biotech PCL.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the DOD Biotech PCL's sales revenue. A higher gross margin percentage indicates that the DOD Biotech PCL retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the DOD Biotech PCL's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the DOD Biotech PCL's total revenue generated. When comparing the revenue margin year over year, investors can gauge the DOD Biotech PCL's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the DOD Biotech PCL. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the DOD Biotech PCL's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

DOD Biotech PCL Margin History

DOD Biotech PCL Gross marginDOD Biotech PCL Profit marginDOD Biotech PCL EBIT marginDOD Biotech PCL Profit margin
202338.77 %8.39 %1.06 %
202226.16 %-2.12 %-74.16 %
202142.81 %30.61 %4.9 %
202042.79 %33.12 %13.11 %
201951.89 %10.92 %10.98 %
201861.51 %45.71 %45.81 %
201759.98 %38.55 %36.71 %
201653.69 %37.57 %37.75 %
201547.14 %34.24 %33.49 %
201438.11 %27.85 %27.85 %

DOD Biotech PCL Aktienanalyse

What does DOD Biotech PCL do?

DOD Biotech PCL is a Thai biotechnology company specializing in the production of pharmaceuticals, diagnostics, and research products. Established in 2004, the company has become one of the most reputable biotechnology companies in Thailand. Its business model is based on the development and manufacturing of products used in medicine, veterinary medicine, and research. DOD Biotech PLC focuses on continually evolving and adapting its products to meet customer needs. Its main areas of focus are the production of pharmaceuticals, particularly anti-cancer drugs, diabetes medications, cardiovascular medications, and infection treatments. Additionally, the company manufactures diagnostics for disease early detection and precise diagnosis. It also offers a variety of products for research purposes. DOD Biotech PCL has partnerships with several companies in other countries, particularly in Asia and Europe. Its largest partner is the Indian company Sun Pharma, with which it has had a successful collaboration for many years. The company is known for its high-quality standards and is certified to ISO 9001:2015 and follows the Good Manufacturing Practices (GMP) required by the Thai FDA. DOD Biotech PCL has received international recognition, including the Frost & Sullivan Thailand Excellence Award and being recognized as a top 30 company in Thailand in 2020. Over the years, the company has built a loyal customer base that appreciates its high-quality products and excellent customer service. It has a strong online presence to better reach and serve its customers. In summary, DOD Biotech PCL is a leading biotechnology company in Thailand with a wide range of pharmaceuticals, diagnostics, and research products. It has earned an excellent reputation for its high-quality standards and top-notch customer service. With its strong online presence and partnerships with other companies in Asia and Europe, DOD Biotech PCL will undoubtedly remain an important player in the global healthcare market in the future. DOD Biotech PCL ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding DOD Biotech PCL's Profit Margins

The profit margins of DOD Biotech PCL represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of DOD Biotech PCL's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating DOD Biotech PCL's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

DOD Biotech PCL's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When DOD Biotech PCL’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about DOD Biotech PCL stock

How much profit has DOD Biotech PCL made this year?

DOD Biotech PCL has made 7.19 M THB this year.

How has the profit developed compared to last year?

The profit has increased by -101.8% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does DOD Biotech PCL publish its earnings?

DOD Biotech PCL publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of DOD Biotech PCL?

The profits of DOD Biotech PCL are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of DOD Biotech PCL?

You can learn more about the earnings of DOD Biotech PCL by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does DOD Biotech PCL pay?

Over the past 12 months, DOD Biotech PCL paid a dividend of 0.05 THB . This corresponds to a dividend yield of about 2.23 %. For the coming 12 months, DOD Biotech PCL is expected to pay a dividend of 0 THB.

What is the dividend yield of DOD Biotech PCL?

The current dividend yield of DOD Biotech PCL is 2.23 %.

When does DOD Biotech PCL pay dividends?

DOD Biotech PCL pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of DOD Biotech PCL?

DOD Biotech PCL paid dividends every year for the past 0 years.

What is the dividend of DOD Biotech PCL?

For the upcoming 12 months, dividends amounting to 0 THB are expected. This corresponds to a dividend yield of 0 %.

In which sector is DOD Biotech PCL located?

DOD Biotech PCL is assigned to the 'Non-cyclical consumption' sector.

Wann musste ich die Aktien von DOD Biotech PCL kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of DOD Biotech PCL from 5/20/2020 amounting to 0.05 THB, you needed to have the stock in your portfolio before the ex-date on 3/13/2020.

When did DOD Biotech PCL pay the last dividend?

The last dividend was paid out on 5/20/2020.

What was the dividend of DOD Biotech PCL in the year 2023?

In the year 2023, DOD Biotech PCL distributed 0 THB as dividends.

In which currency does DOD Biotech PCL pay out the dividend?

The dividends of DOD Biotech PCL are distributed in THB.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von DOD Biotech PCL

Our stock analysis for DOD Biotech PCL Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of DOD Biotech PCL Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.